The Pharmacodynamics and Pharmacokinetics of Multiple Doses of the New H2-Receptor Antagonist, Roxatidine Acetate, in Healthy Men
1. 请及时下载文件确认是否正确, 系统将在 2026-10-19 16:12:33 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
HB Lassman, I Ho, SK Puri, R Sabo, MR Scheffler
Drugs, 1988
Springer
Summary Roxatidine acetate (HOE 760, TZU 0460) is a new H2-receptor antagonist which is more potent than cimetidine and ranitidine. A randomised, double-blind, placebo-controlled study was conducted in healthy men to determine the effects of multiple oral doses of roxatidine acetate on unstimulated gastric acid secretion, and to assess the preliminary multiple-dose pharmacokinetics of its active desacetyl metabolite. The subjects were randomised to receive either roxatidine acetate 150mg or placebo daily at 9pm for 14 …
